Priovant's Brepocitinib Shows Strong Phase 2 Results in Cutaneous Sarcoidosis
Event summary
- Brepocitinib 45 mg demonstrated a 22.3-point improvement in mean CSAMI-A at Week 16 vs. 0.7-point improvement in placebo (Δ 21.6 P<0.0001).
- 100% of brepocitinib 45 mg patients achieved at least a 10-point improvement on CSAMI-A.
- Priovant plans to initiate a Phase 3 program in cutaneous sarcoidosis in 2026 following FDA engagement.
- Brepocitinib was well tolerated with no Serious Adverse Events and all Adverse Events graded mild or moderate.
The big picture
Priovant's positive Phase 2 results position brepocitinib as a potential first-in-class treatment for cutaneous sarcoidosis, a disease with no approved therapies. The company is now advancing brepocitinib across three autoimmune indications, reinforcing its strategy of targeting high-morbidity diseases with unmet needs. The success of this program could validate Roivant's platform approach to developing novel therapies through its subsidiary companies.
What we're watching
- Regulatory Pathway
- The pace at which Priovant secures FDA agreement for the Phase 3 study will determine the timeline for potential approval.
- Clinical Execution
- Whether Priovant can replicate these results in the larger Phase 3 trial, especially given the small sample size in Phase 2.
- Competitive Positioning
- How brepocitinib's dual TYK2/JAK1 inhibition differentiates it from other treatments in development for cutaneous sarcoidosis.
Related topics